Followers | 144 |
Posts | 27607 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
![](https://investorshub.advfn.com/uicon/33650.png?cb=1628859195)
Friday, February 25, 2022 12:36:25 PM
by Can-Fite BioPharma, Contributor
February 24, 2022 1:09 PM | 3 min read
https://www.benzinga.com/amp/content/25808959
Summary
We are CORRECTING our initiating coverage of Can-Fite BioPharma Ltd. (“Can Fite” or the “company”), a clinical-stage pharmaceutical company, with an OUTPERFORM rating and $6.00 price target (CORRECTION from the previous, initiated $2 price target). With a pipeline of proprietary small molecule drugs treating inflammation, cancer and liver diseases, we believe Can-Fite is poised to register material progress in commercializing its compounds in 2022, including the imminent release of Phase III trial data for the treatment of psoriasis. Further, with a business model predicated on licensing compounds to leading international pharmaceutical players, we believe new contracts and territory expansion will refocus investors on Can-Fite’s myriad positives. As such, we view the risk/reward in CANF as impressive and are initiating coverage with an OUTPERFORM rating and a $6.00 price target.
Key Points
Focused on A3 adenosine receptor (“A3AR”). A3AR has a high incidence in cancer and inflammatory cells, which allows the company’s compounds to target A3AR and destroy the corresponding cells. Given the low expression of A3AR in normal cells, Can-Fite’s proprietary products have demonstrated high levels of safety.
Demonstrating efficacy: First up, psoriasis. The Phase III COMFORT study, which is designed to test Can-Fite’s Piclidenoson compound superiority in treating moderate to severe plaque psoriasis (versus the placebo) and non-inferiority compared to Amgen’s Otezla®®, was completed in January 2022. We expect 120M release of the data, which is set for 1Q22, to be a material catalyst. Psoriasis is a projected $40 billion + market.
Next in cue: Compounds to combat Hepatocellular Carcinoma (“HCC”) and Nonalcoholic steatohepatitis (“NASH”), a type of non-alcoholic fatty liver disease (“NAFLD”). Can-Fite’s second key compound, Namodenoson, is focused on treating HCC (liver cancer) and NASH. After a successful Phase II trial for HCC, Can-Fite is preparing to launch a Phase III Liver cancer study in 1Q22; the liver cancer market is estimated at approximately $3.8 billion.
In January 2022, Can-Fite enrolled their first patient for a Phase IIb trial to test the efficacy and safety of Namodenoson in treating NASH, a growing disease for which there is currently no FDA approved treatment, The market size is projected to be approximately $35 billion by 2025.
Erectile disfunction, cannabis and animal osteoporosis treatments are all in preclinical development.
Can-Fite business models sharesrisks,still offers impressive rewards. Can-Fite is entirely focused on achieving approval for its compounds. The company licenses the commercialization of its compounds for specific territories and ailments, which includes up front and milestone payments and a double-digit royalty rate. Given that there are still crucial territories unpartnered (United States, Western Europe, United Kingdom, Ireland, Japan among others) we see the signing of future licensing deals as key catalysts.
Strong, effective management team.
We project the company will need approximately $10 million in incremental financing in 2023, via either equity offerings or milestone/new territory licensing expansion.
Our Discounted Cash Flow model registers a CANF value of $7.09. We have conservatively projected only Piclidenoson for psoriasis receives regulatory approval in the projected time period and have assumed further dilutive equity raises.
Recent CANF News
- Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson • GlobeNewswire Inc. • 07/01/2024 11:00:00 AM
- Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix • Business Wire • 06/28/2024 11:00:00 AM
- Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver • Business Wire • 06/24/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/10/2024 11:05:22 AM
- Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study • Business Wire • 06/10/2024 11:00:00 AM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 06/07/2024 08:15:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2024 11:03:54 AM
- Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study • Business Wire • 06/05/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/29/2024 11:05:26 AM
- Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases • Business Wire • 05/29/2024 11:00:00 AM
- Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 • Business Wire • 05/27/2024 11:00:00 AM
- Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6 • Business Wire • 05/23/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2024 08:15:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2024 11:03:28 AM
- Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study • Business Wire • 05/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 11:03:03 AM
- Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study • Business Wire • 05/09/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 11:11:47 AM
- Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 • Business Wire • 05/06/2024 11:00:00 AM
- Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal • Business Wire • 04/25/2024 11:00:00 AM
- Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH • Business Wire • 04/15/2024 11:00:00 AM
- Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients • Business Wire • 04/03/2024 11:00:00 AM
- Can-Fite Reports 2023 Financial Results and Clinical Update • Business Wire • 03/28/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 11:27:14 AM
- Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference • Business Wire • 03/11/2024 11:00:00 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM